Mangoceuticals’ MangoRx IP Secures $2.5M Investment From Strategic Investors, Receives Initial $1.75M Tranche

Mangoceuticals, Inc. (NASDAQ: MGRX) announced a $2.5 million investment from two strategic investors into its subsidiary, MangoRx IP Holdings, LLC. The investment will advance the commercialization of the company's antiviral intellectual property portfolio without issuing any common stock, thus not affecting the outstanding shares of Mangoceuticals. The initial tranche of $1.75 million has been received, representing a 17.5% membership interest, with a second tranche of $750,000 for an additional 7.5% interest due by November 28, 2026.